Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells

被引:17
作者
Borg-von Zepelin, M
Zaschke, K
Gross, U
Monod, M
Müller, FMC
机构
[1] Univ Clin Gottingen, Dept Bacteriol, D-37075 Gottingen, Germany
[2] Dept Pediat, Wurzburg, Germany
[3] Inst Mol Biol Infect, Wurzburg, Germany
[4] CHU Vaudois, Serv Dermatol DHURDV, CH-1011 Lausanne, Switzerland
关键词
FK463; adherence; epithelial cells; Candida;
D O I
10.1159/000064921
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Adherence is considered a major virulence trait of Candida albicans. FK463 is a new investigational intravenous antifungal of the 'candin family' with potent in vitro and in vivo activity against Candida spp. Objective: The aim of the present study was to investigate the effect of Micafungin (FK463) on Candida adherence to epithelial cells of azole-sensitive and azole-resistant C. albicans isolates. Methods: An in vitro assay using microtest plate technology and fluorescence measurement was developed to compare the adherence of C. albicans SC5314 and of paired C. albicans isolates to epithelial cells in the presence and in the absence of FK463. Results: FK463 showed a marked inhibitory effect on the adherence of C albicans SC5314. The addition of FK463 reduced the adherence of C. albicans SC5314 to 90% of the value of control without drug. A dose-dependent adherence inhibition was observed with FK463 in the range of 10-0.015 mug ml(-1). The comparison of paired C. albicans isolates, either a fluconazole-susceptible and a fluconazole-resistant isolate of one patient, revealed no significant difference in the adherence behavior between azole-susceptible and azole-resistant. Conclusion: Micafungin (FK463) has the capacity to reduce adherence of C. albicans azole-susceptible and azole-resistant strains to epithelial cells. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 21 条
  • [1] HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases
    Borg-von Zepelin, M
    Meyer, I
    Thomssen, R
    Würzner, R
    Sanglard, D
    Telenti, A
    Monod, M
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) : 747 - 751
  • [2] BORGVONZEPELIN M, 1995, MYCOSES, V38, P339, DOI 10.1111/j.1439-0507.1995.tb00062.x
  • [3] PUTATIVE VIRULENCE FACTORS OF CANDIDA-ALBICANS
    CUTLER, JE
    [J]. ANNUAL REVIEW OF MICROBIOLOGY, 1991, 45 : 187 - 218
  • [4] AN ENZYME-LINKED-IMMUNOSORBENT-ASSAY FOR QUANTIFYING ADHERENCE OF CANDIDA TO HUMAN VASCULAR ENDOTHELIUM
    FILLER, SG
    DER, LC
    MAYER, CL
    CHRISTENSON, PD
    EDWARDS, JE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (04) : 561 - 566
  • [5] FONZI WA, 1993, GENETICS, V134, P717
  • [6] Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains
    Franz, R
    Kelly, SL
    Lamb, DC
    Kelly, DE
    Ruhnke, M
    Morschhäuser, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) : 3065 - 3072
  • [7] Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
    Ikeda, F
    Wakai, Y
    Matsumoto, S
    Maki, K
    Watabe, E
    Tawara, S
    Goto, T
    Watanabe, Y
    Matsumoto, F
    Kuwahara, S
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 614 - 618
  • [8] Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
    Maenza, JR
    Merz, WG
    Romagnoli, MJ
    Keruly, JC
    Moore, RD
    Gallant, JE
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (01) : 28 - 34
  • [9] Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice
    Maesaki, S
    Hossain, MA
    Miyazaki, Y
    Tomono, K
    Tashiro, T
    Kohno, S
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) : 1728 - 1730
  • [10] In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
    Mikamo, H
    Sato, Y
    Tamaya, T
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) : 485 - 487